Seeking Alpha
28 Oct 2026, 21:50 UTC · 1h ago
Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
Impact · against what's priced in
The launch of TUDRIQEV confirms the successful regulatory approval of RP1, which the market had previously declined to price in. This shifts the company's fundamental valuation from a binary regulatory gamble to a commercial execution story.
- REPL+0.70
Challenges what's priced in
- The price assumes
A successful FDA approval of RP1 by the August 2 decision date
The company is now reporting earnings following the launch of TUDRIQEV, meaning the FDA approval that the market previously declined to assume has occurred.
What REPL's price assumes · Sep 23
Top 1 mover · tap to explore
